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In Alzheimer disease, the gap between excellence of diagnostics and efficacy of therapy
is wide. Despite sophisticated imaging and biochemical markers, the efficacy of available
therapeutic options is limited. Here we examine the possibility that assessment of
endogenous catecholamine levels in cerebrospinal fluid (CSF) may fuel new therapeutic
strategies. In reviewing the available literature, we consider the effects of levodopa,
monoamine oxidase inhibitors, and noradrenaline (NE) modulators, showing disparate
results. We present a preliminary assessment of CSF concentrations of dopamine (DA)
and NE, determined by HPLC, in a small dementia cohort of either Alzheimer’s disease
(AD) or frontotemporal dementia patients, compared to control subjects. Our data reveal
detectable levels of DA, NE in CSF, though we found no significant alterations in the
dementia population as a whole. AD patients exhibit a small impairment of the DA
axis and a larger increase of NE concentration, likely to represent a compensatory
mechanism. While waiting for preventive strategies, a pragmatic approach to AD may
re-evaluate catecholamine modulation, possibly stratified to dementia subtypes, as part
of the therapeutic armamentarium.
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Introduction
In Alzheimer’s disease (AD), efficacious therapies are elusive. Currently approvedmolecules include
acetylcholinesterase inhibitors (AChE-I, such as donepezil, rivastigmine, and galantamine) and the
uncompetitive N-methyl--aspartate (NMDA) glutamate antagonist memantine. These all have
demonstrated only weak effects on cognitive functions. Nevertheless, in the absence of evidence-
based novel approaches, these drugs remain central to dementia care. To note, recent reports confirm
their safe profile, even in Parkinson’s disease (PD) dementia complex (Emre et al., 2014).
In addition, some innovations have been proposed, including newly designed hybrids or alter-
native routes of administration (Bhavna et al., 2014; Thiratmatrakul et al., 2014). While some
authors advocate a more extensive utilization of memantine, definitive data on the glutamatergic
transmission involvement in AD are incomplete. Moreover, clinical results have indicated only
temporarily limited or disappointing effects of memantine. In an ample series of mild to moderate
AD, there were no significant differences in the groups receiving memantine alone or memantine
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plus alpha tocopherol (Dysken et al., 2014). Thus, the dictum
remains that, unfortunately: “the more the disease progresses,
the more the ineffectiveness of anti-dementia drugs emerges”
(Esposito et al., 2013).
The modern diagnostic paradigm has fueled huge investments
in strategies to immunize against the amyloid burden. But, as
recently stated, even “BACE inhibitors might reveal as a water-
shed despite premises and hopes” (Yan and Vassar, 2014); and
inhibitors of γ-secretase, including tarenflurbil or semagacestat,
“were discontinued due to their lack of cognitive improvement or
unacceptable side effects” (Mancuso et al., 2011).
That said, we are witnessing an impressive increase of our diag-
nostic capability. FDG- and amyloid-PET imaging (Lista et al.,
2014) have improved the “early – and differential – diagnosis
of dementia” (Perani et al., 2014). Cerebrospinal fluid (CSF)
biomarkers that reflect the core pathology of AD (De Souza et al.,
2014) appear to facilitate an etiological diagnosis even in the
prodromal stages of the disorder.
On one hand, an early diagnosis might induce behavior change
(e.g., abolition of risk factors, changes in life style). The identifica-
tion of individuals at risk of developing dementia among people
with subjective cognitive complaints or mild cognitive impair-
ment would certainly influences social habits. On the other hand,
such a diagnosis will create expectancies that may be difficult to
fulfill.
Does the capability “to tackle initial steps of the deranged path-
way decades before the clinical explosion” translate into better
prognosis? Hampel et al. (2014) claims: “there is a mounting
consensus that such disease-modifying compounds and/or inter-
ventions are more likely to be effectively administered as early
as possible in the cascade of pathogenic processes preceding and
underlying the clinical expression of AD.” Well, which molecules
became available and were marketed in the last decade?
Several concomitant biochemical alterations appear to be more
realistic targets. These include the malfunctioning insulin sig-
naling (Dar et al., 2014; Wirz et al., 2014), the dysfunction
of mitochondria-associated membranes, cerebrovascular changes
with altered permeability (Diomedi and Stefani, 2014), and dis-
turbed energy metabolism. More radically, some leaders in the
functional neurosurgery world are proposing deep brain stim-
ulation of anterior cingulate cortex (or the nucleus basalis of
Meynert) (Hardenacke et al., 2013; Laxton and Lozano, 2013).
This is not the appropriate context to discuss these initiatives (so
far, limited to a few patients).
The central hypothesis governing this manuscript is that we
might profitably investigate catecholaminergic transmission in
AD patients.
It is already established that deficit in endogenous catechol
pathways affects cortical plasticity. It was shown, in routine studies
with paired pulse protocols, that levodopa and rotigotine might
partially revert electrophysiological disturbances attributable to
cholinergic deficit. Martorana and Koch recently suggested “the
dopaminergic system may well be involved in the occurrence of
cognitive decline, often being predictive of rapidly progressive
forms of AD” (Koch et al., 2012; Martorana et al., 2013).
These recent statements have returned our attention to
catecholamine-mediated functions in aging brain disease.
In addition, we are aware of the putative key role of noradrenaline
(NE) in shaping the so-called “cognitive reserve” (Robertson,
2013) and the well-known correlation of nigrostriatal impairment
with dementia in movement disorders (McKeith et al., 2007;
Tatsch and Poepper, 2013). These reflections inspired the current
manuscript.
Catecholamine Therapy in AD
MAO Inhibitors
The therapeutic potential of monoamine oxidase inhibitors
(MAOI) inADhas been suggested in light of their neuroprotective
properties and augmenting effect on monoaminergic transmis-
sion (Klegeris and McGeer, 2000). In the early 90s, Agnoli et al.
(1992) performed one of the first pilot studies, followed by several
groups (Tolbert and Fuller, 1996; Freedman et al., 1998; Tariot
et al., 1998) but results were quite inconsistent (Thomas, 2000).
A promising double-blind, randomized, multicenter trial, for
example, provided some encouraging results (Sano et al., 1997,
although the baseline score on MMSE was biased).
A 2003 Cochrane review on selegiline and AD (Birks and
Flicker, 2003) admitted that, “despite its initial promise, and its
role in the treatment of PD sufferers, selegiline for AD has been
proved disappointing.” The authors concluded “no evidence of
a significant adverse event profile” but also “no evidence of a
clinically meaningful benefit for AD” (Birks and Flicker, 2003).
Recent experience is suggesting new potential avenues. We are
now aware of the limitations hampering old trials, such as the
methodological problems in complex disease like dementia, and
the difficulty in interpreting results in the absence of reliable
biomarkers (some of which are now available). In other words, it is
nowpossible to pursue trialswith: (a) small cohorts (enrolling spe-
cific disease subtype, avoiding the bias of non-specific inclusion
of mixed dementia type), (b) correlation between biomarkers and
cognitive scores – not dominated by mere analogic scoring (such
as MMSE scale).
In addition, rasagiline, whose proteiform neuroprotective abil-
ities are undisputed, acquired the potential status of a disease-
modifying agent in PD (Hanagasi et al., 2011; Kupershmidt et al.,
2012). Recent years are witnessing the possibility that these agents
induce protective effects on cognitive performance not merely in
PD, but also in normal brain aging.
Not surprisingly, the pipeline of several small companies is
recently developing hybrids, combining propargylamine-derived
molecules with AChE-I (Zheng et al., 2012; Lu et al., 2013).
This strategy is summarized byBolea et al. (2013): the paradigm
by the Food and Drug Administration-approved drugs based on
the “one drug, one target” (donepezil, galantamine, and rivastig-
mine) might be rephrased into the “one drug, multiple targets”
(hence, “a variety of hybrid compounds acting on very diverse
targets”) (Schneider et al., 1993; Bolea et al., 2013).
Levodopa and Dopamine Agonists
A direct involvement of dopamine in AD was inferred by sev-
eral pre-clinical, experimental contributions. Himeno presented
striking data, showing that the DA agonist apomorphine, in
a transgenic murine AD model, not only accelerated amyloid
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degradation and protected hippocampal neurons from oxidative
stress, but also “restored the memory dysfunctions and improved
the major pathological hallmarks” (Himeno et al., 2011). In
another seminal paper (Kadowaki Horita et al., 2013), bilateral
lesions of the dopaminergic input to the prefrontal cortex (PFC)
were produced in rats using 6-hydroxydopamine (6-OHDA).
Cognitive performance was improved by istradefylline treatment,
by increasing dopamine levels in the PFC in both normal and
PFC-lesioned rats.
Several different groups have suggested dopamine as a key
player in the clinical course of AD (Itoh et al., 1996; Kemp-
painen et al., 2003; Kumar and Patel, 2007; Mura et al., 2010).
Kemppainen et al. examined the DA receptor-binding potential
[through PET with the D2/D3 antagonist (11)c FLB 457]; it was
found a reduced binding in the right hippocampus, with a positive
correlation with verbal memory performance and picture naming
(at the Boston Test), supporting studies “to evaluate the efficiency
of dopaminergic medication on patients with early AD.”
Mura et al. (2010) stressed the possibility that pathological
Abeta oligomers may exert a dysfunctional impact on endoge-
nous catecholaminergic transmission, even before the obvious
neurodegenerative structural alterations.
Martorana’s group has highlighted a potential DA deficit (D1-
mediated, at least in part) underlying cognitive impairment. More
intriguingly, levodopa partially restored cortical transmission
(evaluated by TMS tools, Martorana et al., 2008, 2009, 2010,
2011). Levodopa and/or dopamine agonists, such as rotigotine,
whose endogenous binding is not limited to D2-like preferring
sites, can promote modest but significant cognitive amelioration
(Martorana et al., 2013). These findings are not surprising per se.
A large corpus of pharmacological experiments in 6-OHDA-
lesioned rodents demonstrated the efficacy of apomorphine in
reverting perturbed behavioral tasks (such as water-maze), thus
championing the D2–D1 mixed agonist profile. In our experience
with mild PD subjects, levodopa proved effective (or at least
without cognitive counterbalance), whilst selective D2 agonists
might impair short-term verbal memory, attentional-executive
functions, and verbal fluency (Brusa et al., 2003).
Noradrenaline Modulators
Dysfunction of locus coeruleus (LC) is a hallmark of AD (Zarow
et al., 2003; Bekar et al., 2012). It was postulated long ago that
damage to LC noradrenergic neurons (deposition of neurofibril-
lary tangles) might contribute to disease progression (Zweig et al.,
1989).
Noticeably, NE may participate in the pathogenesis of the
amyloid cascade, as suggested in transgenic APP23 mice, when
the classical α(1)-adrenoceptor antagonist prazosin reduced the
generation of amyloid β in N2a cells, and promoted a cascade
of molecular events culminating in benefits to memory function
(Katsouri et al., 2013).
Yet, experimental setting has provided conflicting results.
For example, 1-month treatment with -DOPS, NE precursor,
improved learning in the Morris water-maze test compared with
vehicle-treated mice. -DOPS increased CNS NA levels, and
average latency times in the water-maze test were inversely cor-
related to NA levels (Kalinin et al., 2012).
In patients, prazosin improved behavioral symptoms in AD
patients with agitation/aggression (Wang et al., 2009). Yu et al.
(2011), in a population-based study of individuals with incident
AD, demonstrated that beta-blockers are also associated with
delay of functional decline. In contrast, Gliebus and Lippa (2007)
showed that “a trend for worse delayedmemory retrieval occurred
in patients who were on CNS-active beta-blockers.” Further, beta-
adrenergic agonists were anecdotally shown as “memory rescu-
ing” (Gibbs et al., 2010). These inconsistent findings may be
attributed to two major biases; (a) inconsistent inclusion criteria
and/or (b) concomitant loss of LC functions and ongoing compen-
satorymechanisms (with variable degree depending onAD stage).
In favor of a strong compensatory mechanism is previous
evidence, showing that the increase in NE, following alpha-2
adrenoreceptor blockade in both aging and AD, is detected in
absence of metabolite increase (Raskind et al., 1999). This is
consistent with partial loss of CNS noradrenergic neurons, with
compensatory activation of surviving noradrenergic projections.
A previous elegant work (performed in AD and DLB patients)
corroborated this assumption, showing compensation through
an increase in tyrosine hydroxylase (TH) mRNA expression in
the remaining LC neurons, sprouting of dendrites into the peri-
LC dendritic zone, and sprouting of axonal projections to the
hippocampus as determined by alpha-2-receptor binding (Szot
et al., 2006).
In contrast, some reports (e.g., Fitzgerald, 2010) suggested that,
independent of potential loss of LC cells, brain NE levels may
be elevated in some persons with AD, representing an etiological
factor in some cases of AD, and not merely an epiphenomenon of
the disease.
A recent epigenetic study (Mustapic et al., 2013) favors the
prevalence of compensatory mechanisms, given that the activity
and levels of dopamine beta-hydroxylase was reduced since the
early stages AD (advancing the hypothesis for an indication to NA
reuptake inhibitors).
Preliminary Data
Since 2012, we have started to evaluate CSF catecholamine con-
centrations in dementia patients. Routine lumbar puncture (LP,
Stefani et al., 2005, 2006, 2009, 2012; Chiaravalloti et al., 2014;
Liguori et al., 2014) was performed in patients during brief admis-
sion to our clinic. We also assessed neurocognitive impairment,
exclusion of concomitant iatrogenic or metabolic risk factors, and
carried out neuroimaging (MRI and/or FDG-PET). Dementia
history was<4 years, in line withmild tomoderate stages (Table 1
for major epidemiological features).
In this relatively small cohort of patients, we analyzed the CSF
concentration of DA and NE [plus some major metabolites of
DA and 5-hydroxytriptamine (5-HT) namely homovanillic acid
(HVA) and 5-hydroxyindolacetic acid (5-HIAA), previously indi-
cated as possible biomarkers correlate with behavioral distur-
bances].
An age-matched control cohort was composed of patients
with other neurological diseases (mostly radiculopathies) and
manifesting no cognitive decline (mean MMSE 29.7, data not
shown).
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TABLE 1 | Epidemiological main features of the studied populations (as a
whole and split into AD-like vs. FTD-like).
Age (years) Education
(years)
Disease duration
(months)
MMSE
(score/30)
DET (n= 40) 69.804.16 7.573.54 29.7516.43 21.183.00
AD (n= 26) 70.274.43 7.312.74 28.9216.07 21.103.69
FTD (n= 14) 68.933.58 8.074.78 31.5418.28 21.342.46
P 0.21 0.90 0.80 0.94
TABLE 2 | Main CSF results (concentrations are expressed in nanomoles
per liter).
DA NE HVA 5-HIAA HVA/
5-HIAA
DET (n= 40) 0.190.24 0.660.28 81.63
143.51
43.71
19.13
1.66
3.28
DA NE
AD (n= 26) 0.130.12 0.700.32
FTD (n= 14) 0.300.35 0.560.15
P 0.06 0.20
DA NE
CTR (n=16) 0.671.43 0.490.10
P vs. AD 0.10 0.01
P vs. FTD 0.91 0.14
For the meantime, the first analysis revealed non-significant
alterations in catecholamine CSF levels; nevertheless, demented
patients showed the tendency toward a decreased DA/NE ratio
with respect to controls.
In light of patients’ clinical profile ascertained along 2-year
follow-up, and after FGD-PET completion and the acquisition of
the complete CSF profile (including the assessment of Abeta 1–42,
total tau, and phospho-tau proteins), the dementia group was
subdivided into: AD-type (n= 26) and frontotemporal dementia
(FTD) (n= 14; see Table 2). Table 2 reflects this more selective
analysis.
The tendency for a lower CSF DA concentration was strictly
confined to the AD-like subtype. More importantly, the AD group
showed a significant increase of NE concentration; conversely, the
HVA/5-HIAA ratios, investigated in previous papers as a potential
biomarker for behavioral FTD subtype, in our hands revealed no
difference among studied groups.
Discussion and Conclusion
1. Thismanuscript has tried to shed new lights on catecholamine-
based treatment in AD. Asides from the opportunity to mod-
ulate dopamine-sensitive signs in patients attributable to LBD
(not addressed here), recent data support a renewed interest
around the usefulness of dopaminergic agents in handling
cortical dementia, particularly AD-type.
This brief literature review imposes an extreme caution. Argu-
ments to build up a therapeutic indication are still poor. After
all, levodopa-centered therapy as add-on treatment in a cocktail
regimen for AD patients has been tested only in observational
clinical studies (or centered on electrophysiological indexes) and
in very limited trials.
Our CSF data indicate that AD patients have increased NE
levels, relative to aged, neurological controls without dementia.
These findings suggest compensatory changes, but do not offer
a simple therapeutic answer. In fact, they could be attributed,
per se, to non-specific processes, representing a mere correlate
of senescence (in light of a well-known intrinsic vulnerability of
VTA/SN/LC regions in any aging brain).
In addition, a precise pathogenesis role of catecholamine along
the course of AD is still questionable. Strong is the evidence, for
instance, on a perturbed catecholamine vesicular system shared by
different movement disorders, but not playing relevant role in AD
(Goldstein et al., 2013).
2. In the short term, as sample size increases, we will assess
the relation of CSF pattern to specific clinical phenotypes; in
this content, longitudinal assessment may facilitate the under-
standing of the impact of DA- or NE-based therapy on specific
behavioral traits.
Our students recall the clinical presentation of Alois
Alzheimer’s patient, D. Frau Auguste, dominated by emotional
distress and infidelity/excessive jealousy, before or in combination
with cognitive symptoms (Geda et al., 2013). Still nowadays,
despite the fact that we gather a clinical diagnosis of “probable
AD” decades in advance, psychic alterations are prominent and
critical, mostly in early-onset AD.
Although disease-modifying therapies are the “Holy Grail”
to pursue symptomatic therapies, addressing neuropsychiatric
aspects are also important for the quality of life of patients and
caregivers (Geerts et al., 2013). Amongst the unmet needs, are
the relevance of delusions (not simply attributable to psychotic
derangement, Ismail et al., 2011.) and the severity of apathy. Bor-
roni et al. (2010) in reminding that >50% AD patients manifest
psychiatric disturbances such as psychosis, depression, agitation,
disinhibition, aggression, hyperactivity, and socially intrusive
behaviors, consider likely candidates the involvement of DA- or
serotonin-related pathways and associated genetic variabilities.
Yet, these assumptions do not translate into operative pharmaco-
logical strategies. As amatter of fact, the current attitude shared by
general practitioners (adding SSRI or SNRI or trazodone) is just
empirical (Mizukami et al., 2009; Sepehry et al., 2012).
Particularly elusive is the treatment of apathy. As reviewed
by Vilalta-Franch et al. (2013), apathy syndrome in Alzheimer’s
disease (ASAD) has a prevalence and incidence/year respectively
21 and 10.6%; it has been reported that ASAD persisted in 61.2%
of patients after 1 year, causing an increased functional disability,
but no relationship with cognitive impairment or increased care-
giver burden was detected. Apathy treatment, despite occasional
trial with modafinil or methylphenidate, remains a challenge
(Herrmann et al., 2008; Padala et al., 2010; Frakey et al., 2012).
3. A comprehensive review (Schneider et al., 2014), examining
late-stage AD drug development from 1984 to 2013, reminds
that “the predominant drug targets have been the cholinergic
system and the amyloid cascade.” Yet, adjourned “regulatory
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guidance and oversight have evolved to allow for enrichment
of early-stage AD trial samples using biomarkers and phase-
specific outcomes.” Hence, although “validated drug targets
for AD remain to be developed (and only drugs that affect
an aspect of cholinergic function have shown consistent, but
modest, clinical effects in late-phase trials), there is oppor-
tunity for substantial improvements in drug discovery and
clinical development methods.”
It is uncertain whether this hope of catching the disease in its
presymptomatic phase (Wirz et al., 2014) is realistic. Of course,
we should agree with opinion leader as Hampel when declar-
ing that treatments “need to be applied before various molecular
mechanisms converge into an irreversible pathway leading to
morphological/structural damages” (Hampel et al., 2014). Yet,
most modern health systems cannot tolerate decades of diag-
nostic protocols whose therapeutic effectiveness is unvalidated.
The cost of one new drug ranges from an optimistic $2.0 billion
to $5.7 billion (95% CI $1.5–2.9 billion) (Scott et al., 2014).
In other words, we doubt that “advances in the study of pre-
clinical AD have driven the recognition that efficacy of at least
some AD therapies may depend on initiation of treatment before
clinical manifestation of disease, leading to a new era of AD
prevention research” (Langbaum et al., 2013).
Truly enough, upcoming years will deal with a much more
pragmatic vision of AD therapy, which explore treatable impair-
ment such as vascular co-morbidity (Diomedi and Stefani, 2014)
or insulin dysfunction (Wirz et al., 2014).
In conclusion, and despite conflicting findings, there is
the opportunity to foresee extended and blind trials dedi-
cated to clarify to what extent MAOI, dopamine agonists,
levodopa, or NE modulators may act synergically with AChE-
I since the first AD stages and/or in selected behavioral
phenotypes.
References
Agnoli, A., Fabbrini, G., Fioravanti, M., andMartucci, N. (1992). CBF and cognitive
evaluation of Alzheimer type patients before and after IMAO-B treatment: a
pilot study. Eur. Neuropsychopharmacol. 2, 31–35. doi:10.1016/0924-977X(92)
90033-5
Bekar, L. K., Wei, H. S., and Nedergaard, M. (2012). The locus coeruleus-
norepinephrine network optimizes coupling of cerebral blood volume with
oxygen demand. J. Cereb. Blood Flow Metab. 32, 2135–2145. doi:10.1038/jcbfm.
2012.115
Bhavna, Md, S., Ali, M., Ali, R., Bhatnagar, A., Baboota, S., et al. (2014). Donepezil
nanosuspension intended for nose to brain targeting: in vitro and in vivo
safety evaluation. Int. J. Biol. Macromol. 67, 418–425. doi:10.1016/j.ijbiomac.
2014.03.022
Birks, J., and Flicker, L. (2003). Selegiline for Alzheimer’s disease. Cochrane
Database Syst. Rev. 1:CD000442. doi:10.1002/14651858.CD000442
Bolea, I., Gella, A., and Unzeta, M. (2013). Propargylamine-derived multitarget-
directed ligands: fighting Alzheimer’s disease with monoamine oxidase
inhibitors. J. Neural Transm. 120, 893–902. doi:10.1007/s00702-012-0948-y
Borroni, B., Costanzi, C., and Padovani, A. (2010). Genetic susceptibility to behav-
ioral and psychological symptoms in Alzheimer disease. Curr. Alzheimer Res. 7,
158–164. doi:10.2174/156720510790691173
Brusa, L., Bassi, A., Stefani, A., Pierantozzi, M., Peppe, A., Caramia, M. D., et al.
(2003). Pramipexole in comparison to l-dopa: a neuropsychological study.
J. Neural Transm. 110, 373–380. doi:10.1007/s00702-002-0811-7
Chiaravalloti, A., Stefani, A., Fiorentini, A., Lacanfora, A., Stanzione, P., and
Schillaci, O. (2014). Do CSF levels of t-Tau, p-Tau and β1–42 amyloid
correlate with dopaminergic system impairment in patients with a clinical
diagnosis of Parkinson disease? A 123I-FP-CIT study in the early stages of
the disease. Eur. J. Nucl. Med. Mol. Imaging 41, 2137–2143. doi:10.1007/
s00259-014-2841-4
Dar, T. A., Sheikh, I. A., Ganie, S. A., Ali, R., Singh, L. R., Gan, S. H., et al.
(2014). Molecular linkages between diabetes and Alzheimer’s disease: current
scenario and future prospects. CNS Neurol. Disord. Drug Targets 13, 290–298.
doi:10.2174/18715273113126660135
De Souza, L. C., Sarazin, M., Teixeira-Júnior, A. L., Caramelli, P., Santos, A. E.,
and Dubois, B. (2014). Biological markers of Alzheimer’s disease. Arq. Neurop-
siquiatr. 72, 227–231. doi:10.1590/0004-282X20130233
Diomedi, M., and Stefani, A. (2014). Hemodynamic changes in Alzheimer’s disease:
a leading role behind the curtain? Commentary on “CSF Aβ1-42 combined with
neuroimaging biomarkers in the early detection, diagnosis and prediction of
Alzheimer’s disease” by Lista et al. Alzheimers Dement. doi:10.1016/j.jalz.2014.
10.004
Dysken, M. W., Sano, M., and Asthana, S. (2014). Effect of vitamin E and meman-
tine on functional decline in Alzheimer disease: the TEAM-AD VA cooperative
randomized trial. JAMA 311, 33–44. doi:10.1001/jama.2013.282834
Emre, M., Poewe, W., De Deyn, P. P., Barone, P., Kulisevsky, J., Pourcher, E.,
et al. (2014). Long-term safety of rivastigmine in Parkinson disease dementia:
an open-label, randomized study. Clin. Neuropharmacol. 37, 9–16. doi:10.1097/
WNF.0000000000000010
Esposito, Z., Belli, L., Toniolo, S., Sancesario, G., Bianconi, C., and Martorana, A.
(2013). Amyloid β, glutamate, excitotoxicity in Alzheimer’s disease: are we on
the right track? The more the disease progresses, the more the uneffectiveness
of antidementia drugs emerges. CNS Neurosci. Ther. 19, 549–555. doi:10.1111/
cns.12095
Fitzgerald, P. J. (2010). Is elevated norepinephrine an etiological factor in some
cases of Alzheimer’s disease? Curr. Alzheimer Res. 7, 506–516. doi:10.2174/
156720510792231775
Frakey, L. L., Salloway, S., Buelow, M., and Malloy, P. J. (2012). A randomized,
double-blind, placebo-controlled trial of modafinil for the treatment of apathy
in individuals with mild-to-moderate Alzheimer’s disease. J. Clin. Psychiatry 73,
796–801. doi:10.4088/JCP.10m06708
Freedman, M., Rewilak, D., Xerri, T., Cohen, S., Gordon, A. S., Shandling, M.,
et al. (1998). L-deprenyl in Alzheimer’s disease: cognitive and behavioral effects.
Neurology 50, 660–668. doi:10.1212/WNL.50.3.660
Geda, Y. E., Schneider, L. S., Gitlin, L. N., Miller, D. S., Smith, G. S., Bell, J., et al.
(2013). Neuropsychiatric symptoms in Alzheimer’s disease: past progress and
anticipation of the future. Alzheimers Dement. 9, 602–608. doi:10.1016/j.jalz.
2012.12.001
Geerts, H., Roberts, P., Spiros, A., and Carr, R. (2013). A strategy for devel-
oping new treatment paradigms for neuropsychiatric and neurocognitive
symptoms in Alzheimer’s disease. Front. Pharmacol. 4:47. doi:10.3389/fphar.
2013.00047
Gibbs, M. E., Maksel, D., Gibbs, Z., Hou, X., Summers, R. J., and Small, D.
H. (2010). Memory loss caused by beta-amyloid protein is rescued by a
beta(3)-adrenoceptor agonist. Neurobiol. Aging 31, 614–624. doi:10.1016/j.
neurobiolaging.2008.05.018
Gliebus, G., and Lippa, C. F. (2007). The influence of beta-blockers on delayed
memory function in people with cognitive impairment. Am. J. Alzheimers Dis.
Other Demen. 22, 57–61. doi:10.1177/1533317506295889
Goldstein, D. S., Sullivan, P., Holmes, C., Miller, G. W., Alter, S., Strong, R., et al.
(2013). Determinants of buildup of the toxic dopamine metabolite DOPAL in
Parkinson’s disease. J. Neurochem. 126, 591–603. doi:10.1111/jnc.12345
Hampel, H., Lista, S., Teipel, S. J., Garaci, F., Nisticò, R., Blennow, K., et al.
(2014). Perspective on future role of biological markers in clinical therapy
trials of Alzheimer’s disease: a long-range point of view beyond 2020. Biochem.
Pharmacol. 88, 426–449. doi:10.1016/j.bcp.2013.11.009
Hanagasi, H. A., Gurvit, H., Unsalan, P., Horozoglu, H., Tuncer, N., Feyzioglu, A.,
et al. (2011). The effects of rasagiline on cognitive deficits in Parkinson’s disease
patients without dementia: a randomized, double-blind, placebo-controlled,
multicenter study.Mov. Disord. 26, 1851–1858. doi:10.1002/mds.23738
Hardenacke, K., Kuhn, J., Lenartz, D., Maarouf, M., Mai, J. K., Bartsch, C., et al.
(2013). Stimulate or degenerate: deep brain stimulation of the nucleus basalis
Frontiers in Aging Neuroscience | www.frontiersin.org May 2015 | Volume 7 | Article 675
Stefani et al. Catecholamine-oriented therapies in Alzheimer’s disease
Meynert in Alzheimer dementia. World Neurosurg. 80, e35–e43. doi:10.1016/j.
wneu.2012.12.005
Herrmann, N., Rothenburg, L. S., Black, S. E., Ryan, M., Liu, B. A., Busto, U.
E., et al. (2008). Methylphenidate for the treatment of apathy in Alzheimer
disease: prediction of response using dextroamphetamine challenge. J. Clin.
Psychopharmacol. 28, 296–301. doi:10.1097/JCP.0b013e318172b479
Himeno, E., Ohyagi, Y., Ma, L., Nakamura, N., Miyoshi, K., Sakae, N., et al. (2011).
Apomorphine treatment in Alzheimer mice promoting amyloid-b degradation.
Ann. Neurol. 69, 248–256. doi:10.1002/ana.22319
Ismail, Z., Nguyen,M.Q., Fischer, C. E., Schweizer, T. A.,Mulsant, B. H., andMamo,
D. (2011). Neurobiology of delusions in Alzheimer’s disease. Curr. Psychiatry
Rep. 13, 211–218. doi:10.1007/s11920-011-0195-1
Itoh, A., Nitta, A., Nadai, M., Nishimura, K., Hirose, M., Hasegawa, T., et al. (1996).
Dysfunction of cholinergic and dopaminergic neuronal systems in beta-amyloid
protein-infused rats. J. Neurochem. 66, 1113–1117. doi:10.1046/j.1471-4159.
1996.66031113.x
Kadowaki Horita, T., Kobayashi, M., Mori, A., Jenner, P., and Kanda, T. (2013).
Effects of the adenosine A2A antagonist istradefylline on cognitive performance
in rats with a 6-OHDA lesion in prefrontal cortex. Psychopharmacology (Berl.)
230, 345–352. doi:10.1007/s00213-013-3158-x
Kalinin, S., Polak, P. E., Lin, S. X., Sakharkar, A. J., Pandey, S. C., and Feinstein, D.
L. (2012). The noradrenaline precursor L-DOPS reduces pathology in a mouse
model of Alzheimer’s disease. Neurobiol. Aging 33, 1651–1663. doi:10.1016/j.
neurobiolaging.2011.04.012
Katsouri, L., Vizcaychipi, M. P., McArthur, S., Harrison, I., Suárez-Calvet, M., Lleo,
A., et al. (2013). Prazosin, an α(1)-adrenoceptor antagonist, prevents memory
deterioration in the APP23 transgenic mouse model of Alzheimer’s disease.
Neurobiol. Aging 34, 1105–1115. doi:10.1016/j.neurobiolaging.2012.09.010
Kemppainen, N., Laine, M., Laakso, M. P., Kaasinen, V., Någren, K., Vahlberg,
T., et al. (2003). Hippocampal dopamine D2 receptors correlate with memory
functions in Alzheimer’s disease. Eur. J. Neurosci. 18, 149–154. doi:10.1046/j.
1460-9568.2003.02716.x
Klegeris, A., and McGeer, P. L. (2000). R-(-)-Deprenyl inhibits monocytic THP-1
cell neurotoxicity independently of monoamine oxidase inhibition. Exp. Neurol.
166, 458–464. doi:10.1006/exnr.2000.7517
Koch, G., Di Lorenzo, F., Bonnì, S., Ponzo, V., Caltagirone, C., and Martorana, A.
(2012). Impaired LTP- but not LTD-like cortical plasticity in Alzheimer’s disease
patients. J. Alzheimers Dis. 31, 593–599. doi:10.3233/JAD-2012-120532
Kumar, U., and Patel, S. C. (2007). Immunohistochemical localization of dopamine
receptor subtypes (D1ReD5R) in Alzheimer’s disease brain. Brain Res. 1131,
187–196. doi:10.1016/j.brainres.2006.10.049
Kupershmidt, L., Amit, T., Bar-Am, O., Weinreb, O., and Youdim, M. B. (2012).
Multi-target, neuroprotective and neurorestorative M30 improves cognitive
impairment and reduces Alzheimer’s-like neuropathology and age-related
alterations in mice. Mol. Neurobiol. 46, 217–220. doi:10.1007/
s12035-012-8304-7
Langbaum, J. B., Fleisher, A. S., Chen, K., Ayutyanont, N., Lopera, F., Quiroz, Y.
T., et al. (2013). Ushering in the study and treatment of preclinical Alzheimer
disease. Nat. Rev. Neurol. 9, 371–381. doi:10.1038/nrneurol.2013.107
Laxton, A. W., and Lozano, A. M. (2013). Deep brain stimulation for the treatment
of Alzheimer disease and dementias.World Neurosurg. 80, e1–e8. doi:10.1016/j.
wneu.2012.06.028
Liguori, C., Stefani, A., Sancesario, G., Sancesario, G. M., Marciani, M. G., and
Pierantozzi, M. (2014). CSF lactate levels, τ proteins, cognitive decline: a
dynamic relationship in Alzheimer’s disease. J. Neurol. Neurosurg. Psychiatr.
doi:10.1136/jnnp-2014-308577
Lista, S., Garaci, F. G., Ewers, M., Teipel, S., Zetterberg, H., Blennow, K., et al.
(2014). CSF Aβ1-42 combined with neuroimaging biomarkers in the early
detection, diagnosis and prediction of Alzheimer’s disease. Alzheimers Dement.
10, 381–392. doi:10.1016/j.jalz.2013.04.506
Lu, C., Zhou, Q., Yan, J., Du, Z., Huang, L., and Li, X. (2013). A novel series of
tacrine-selegiline hybrids with cholinesterase and monoamine oxidase inhibi-
tion activities for the treatment of Alzheimer’s disease. Eur. J. Med. Chem. 62,
745–753. doi:10.1016/j.ejmech.2013.01.039
Mancuso, C., Siciliano, R., Barone, E., Butterfield, D. A., and Preziosi, P. (2011).
Pharmacologists and Alzheimer disease therapy: to boldly go where no scien-
tist has gone before. Expert Opin. Investig. Drugs 20, 1243–1261. doi:10.1517/
13543784.2011.601740
Martorana, A., Stefani, A., Palmieri,M. G., Esposito, Z., Bernardi, G., Sancesario, G.,
et al. (2008). L-dopa modulates motor cortex excitability in Alzheimer’s disease
patients. J. Neural Transm. 115, 1313–1319. doi:10.1007/s00702-008-0082-z
Martorana, A., Mori, F., Esposito, Z., Kusayanagi, H., Monteleone, F., Codecà,
C., et al. (2009). Dopamine modulates cholinergic cortical excitability in
Alzheimer’s disease patients. Neuropsychopharmacology 34, 2323–2328. doi:10.
1038/npp.2009.60
Martorana, A., Esposito, Z., and Koch, G. (2010). Beyond the cholinergic hypoth-
esis: do current drugs work in Alzheimer’s disease? CNS Neurosci. Ther. 16,
235–245. doi:10.1111/j.1755-5949.2010.00175.x
Martorana, A., Semprini, R., and Koch, G. (2011). “Clinical profile of Alzheimer’s
disease non-responder patient,” in Advanced Understanding of Neuro-
degenerative Diseases, ed. C. Raymond Chuen-Chung (Rijeka: InTech),
156–168. [ISBN 978-953-307-529-7].
Martorana, A., Di Lorenzo, F., Esposito, Z., Lo Giudice, T., Bernardi, G., Calt-
agirone, C., et al. (2013). Dopamine D2-agonist rotigotine effects on cortical
excitability and central cholinergic transmission in Alzheimer’s disease patients.
Neuropharmacology 64, 108–113. doi:10.1016/j.neuropharm.2012.07.015
McKeith, I., O’Brien, J., Walker, Z., Tatsch, K., Booij, J., Darcourt, J., et al. (2007).
Sensitivity and specificity of dopamine transporter imaging with 123I.FP-CIT
SPECT in dementia with Lewy bodies: a phase III, multicenter study. Lancet
Neurol. 6, 305–313. doi:10.1016/S1474-4422(07)70057-1
Mizukami, K., Hatanaka, K., Tanaka, Y., Sato, S., and Asada, T. (2009). Therapeutic
effects of the selective serotonin noradrenaline reuptake inhibitor milnacipran
on depressive symptoms in patients with Alzheimer’s disease. Prog. Neuropsy-
chopharmacol. Biol. Psychiatry 33, 349–352. doi:10.1016/j.pnpbp.2008.12.019
Mura, E., Lanni, C., Preda, S., Pistoia, F., Sarà, M., Racchi, M., et al. (2010).
Beta-amyloid: a disease target or a synaptic regulator affecting age-related
neurotransmitter changes? Curr. Pharm. Des. 16, 672–683. doi:10.2174/
138161210790883723
Mustapic, M., Presecki, P., Pivac, N., Mimica, N., Hof, P. R., Simic, G., et al. (2013).
Genotype-independent decrease in plasma dopamine beta-hydroxylase activity
in Alzheimer’s disease. Prog. Neuropsychopharmacol. Biol. Psychiatry 1, 94–99.
doi:10.1016/j.pnpbp.2013.02.002
Padala, P. R., Burke, W. J., Shostrom, V. K., Bhatia, S. C., Wengel, S. P., Potter, J.
F., et al. (2010). Methylphenidate for apathy and functional status in dementia
of the Alzheimer type. Am. J. Geriatr. Psychiatry 18, 371–374. doi:10.1097/JGP.
0b013e3181cabcf6
Perani, D., Schillaci, O., Padovani, A., Nobili, F. M., Iaccarino, L., Della Rosa, P.
A., et al. (2014). A survey of FDG- and amyloid-PET imaging in dementia and
GRADE analysis. Biomed Res. Int. 2014, 785039. doi:10.1155/2014/785039
Raskind, M. A., Peskind, E. R., Holmes, C., and Goldstein, D. S. (1999). Pat-
terns of cerebrospinal fluid catechols support increased central noradrenergic
responsiveness in aging and Alzheimer’s disease. Biol. Psychiatry 46, 756–765.
doi:10.1016/S0006-3223(99)00008-6
Robertson, I. H. (2013). A noradrenergic theory of cognitive reserve: implica-
tions for Alzheimer’s disease. Neurobiol. Aging 34, 298–308. doi:10.1016/j.
neurobiolaging.2012.05.019
Sano, M., Ernesto, C., Thomas, R. G., Klauber, M. R., Schafer, K., Grundman,
M., et al. (1997). A controlled trial of selegiline, alpha-tocopherol, or both as
treatment for Alzheimer’s disease. The Alzheimer’s disease cooperative study.
N. Engl. J. Med. 336, 1216–1222. doi:10.1056/NEJM199704243361704
Schneider, L. S., Mangialasche, F., Andreasen, N., Feldman, H., Giacobini, E., Jones,
R., et al. (2014). Clinical trials and late-stage drug development for Alzheimer’s
disease: an appraisal from 1984 to 2014. Intern. Med. 275, 251–283. doi:10.1111/
joim.12191
Schneider, L. S., Olin, J. T., and Pawluczyk, S. (1993). A double-blind crossover
pilot study of l-deprenyl (selegiline) combined with cholinesterase inhibitor in
Alzheimer’s disease. Am. J. Psychiatry 150, 321–323. doi:10.1176/ajp.150.2.321
Scott, T. J., O’Connor, A. C., Link, A. N., and Beaulieu, T. J. (2014). Economic analy-
sis of opportunities to accelerate Alzheimer’s disease research and development.
Ann. N. Y. Acad. Sci. 1313, 17–34. doi:10.1111/nyas.12417
Sepehry, A. A., Lee, P. E., Hsiung, G. Y., Beattie, B. L., and Jacova, C. (2012). Effect
of selective serotonin reuptake inhibitors in Alzheimer’s disease with comorbid
depression: a meta-analysis of depression and cognitive outcomes. Drugs Aging
29, 793–806. doi:10.1007/s40266-012-0012-5
Stefani, A., Bernardini, S., Panella, M., Pierantozzi, M., Nuccetelli, M., Koch, G.,
et al. (2005). AD with subcortical white matter lesions and vascular dementia:
Frontiers in Aging Neuroscience | www.frontiersin.org May 2015 | Volume 7 | Article 676
Stefani et al. Catecholamine-oriented therapies in Alzheimer’s disease
CSF markers for differential diagnosis. J. Neurol. Sci. 237, 83–88. doi:10.1016/j.
jns.2005.05.016
Stefani, A., Martorana, A., Bernardini, S., Panella, M., Mercati, F., Orlacchio, A.,
et al. (2006). CSF markers in Alzheimer disease patients are not related to the
different degree of cognitive impairment. J. Neurol. Sci. 251, 124–128. doi:10.
1016/j.jns.2006.09.014
Stefani, A., Sancesario, G., Pierantozzi, M., Leone, G., Galati, S., Hainsworth, A.
H., et al. (2009). CSF biomarkers, impairment of cerebral hemodynamics and
degree of cognitive decline in Alzheimer’s and mixed dementia. J. Neurol. Sci.
283, 109–115. doi:10.1016/j.jns.2009.02.343
Stefani, A., Brusa, L., Olivola, E., Pierantozzi,M., andMartorana, A. (2012). CSF and
clinical hallmarks of subcortical dementias: focus on DLB and PDD. J. Neural
Transm. 119, 861–875. doi:10.1007/s00702-012-0820-0
Szot, P., White, S. S., Greenup, J. L., Leverenza, J. B., Peskind, E. R., and Raskind,
M. A. (2006). Compensatory changes in the noradrenergic nervous system in
the locus coeruleus and hippocampus of postmortem subjects with Alzheimer’s
disease and dementia with Lewy bodies. J. Neurosci. 26, 467–478. doi:10.1523/
JNEUROSCI.4265-05.2006
Tariot, P. N., Goldstein, B., Podgorski, C. A., Cox, C., and Frambes, N. (1998).
Short-term administration of selegiline for mild-to-moderate dementia of
the Alzheimer’s type. Am. J. Geriatr. Psychiatry 6, 145–154. doi:10.1097/
00019442-199821000-00008
Tatsch, K., and Poepper, I. (2013). Nigrostriatal dopamine terminal imaging with
dopamine transporter SPCET: an update. J. Nucl. Med. 54, 1331–1338. doi:10.
2967/jnumed.112.105379
Thiratmatrakul, S., Yenjai, C., Waiwut, P., Vajragupta, O., Reubroycharoen, P.,
Tohda,M., et al. (2014). Synthesis, biological evaluation andmolecularmodeling
study of novel tacrine-carbazole hybrids as potential multifunctional agents for
the treatment of Alzheimer’s disease. Eur. J. Med. Chem. 75, 21–30. doi:10.1016/
j.ejmech.2014.01.020
Thomas, T. (2000). Monoamine oxidase-B inhibitors in the treatment of
Alzheimer’s disease.Neurobiol. Aging 21, 343–348. doi:10.1016/S0197-4580(00)
00100-7
Tolbert, S. R., and Fuller, M. A. (1996). Selegiline in treatment of behav-
ioral and cognitive symptoms of Alzheimer disease. Ann. Pharmacother. 30,
1122–1129.
Vilalta-Franch, J., Calvó-Perxas, L., Garre-Olmo, J., Turró-Garriga, O., and López-
Pousa, S. J. (2013). Apathy syndrome in Alzheimer’s disease epidemiology:
prevalence, incidence, persistence, and risk and mortality factors. J. Alzheimers
Dis. 33, 535–543. doi:10.3233/JAD-2012-120913
Wang, L. Y., Shofer, J. B., Rohde, K., Hart, K. L., Hoff, D. J., McFall, Y. H., et al.
(2009). Prazosin for the treatment of behavioral symptoms in patients with
Alzheimer disease with agitation and aggression. Am. J. Geriatr. Psychiatry 17,
744–751. doi:10.1097/JGP.0b013e3181ab8c61
Wirz, K. T., Keitel, S., Swaab, D. F., Verhaagen, J., and Bossers, K. (2014). Early
molecular changes inAlzheimer disease: canwe catch the disease in its presymp-
tomatic phase? J. Alzheimers Dis. 38, 719–740. doi:10.3233/JAD-130920
Yan, R., and Vassar, R. (2014). Targeting the β secretase BACE1 for Alzheimer’s dis-
ease therapy. Lancet Neurol. 13, 319–329. doi:10.1016/S1474-4422(13)70276-X
Yu, J. T., Wang, N. D., Ma, T., Jiang, H., Guan, J., and Tan, L. (2011). Roles of β-
adrenergic receptors in Alzheimer’s disease: implications for novel therapeutics.
Brain Res. Bull. 84, 111–117. doi:10.1016/j.brainresbull.2010.11.004
Zarow, C., Lyness, S. A., Mortimer, J. A., and Chui, H. C. (2003). Neuronal loss
is greater in the locus coeruleus than nucleus basalis and substantia nigra
in Alzheimer and Parkinson diseases. Arch. Neurol. 60, 337–341. doi:10.1001/
archneur.60.3.337
Zheng, H., Amit, T., Bar-Am, O., Fridkin, M., Youdim, M. B., and Mandel, S. A.
(2012). From anti-Parkinson’s drug rasagiline to novel multitarget iron chelators
with acetylcholinesterase and monoamine oxidase inhibitory and neuroprotec-
tive properties for Alzheimer’s disease. J. Alzheimers Dis. 30, 1–16. doi:10.3233/
JAD-2012-120013
Zweig, R. M., Ross, C. A., Hedreen, J. C., Steele, C., Cardillo, J. E., Whitehouse, P. J.,
et al. (1989). Neuropathology of aminergic nuclei in Alzheimer’s disease. Prog.
Clin. Biol. Res. 317, 353–365.
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be
construed as a potential conflict of interest.
Copyright © 2015 Stefani, Olivola, Liguori, Hainsworth, Saviozzi, Angileri, D’Angelo,
Galati and Pierantozzi. This is an open-access article distributed under the terms of the
Creative CommonsAttribution License (CCBY). The use, distribution or reproduction
in other forums is permitted, provided the original author(s) or licensor are credited
and that the original publication in this journal is cited, in accordance with accepted
academic practice. No use, distribution or reproduction is permitted which does not
comply with these terms.
Frontiers in Aging Neuroscience | www.frontiersin.org May 2015 | Volume 7 | Article 677
